β-blockers can be selective for either β, β adrenergic receptor, or to be non-selective. By blocking β receptor it is possible to reduce heart rate, conduction of velocity and contractility. The blocking of β receptor promotes vascular smooth muscle contraction, which results in increase of peripheral resistance. Blockade of the β receptor effectively reduces the sympathetic activity, which results in reduce of the associated platelet-and coagulation activation. This is why a non-selective β-blocker treatment may result in a lower risk of both arterial and venous embolic events.